Building a Peer Valuation Multiple Benchmarking Table from Prospectus Data

The SFC’s updated guidance on price-sensitive information disclosure in late 2024, coupled with the HKEX’s tightened Sponsor Due Diligence Standards under Chapter 3 of the Listing Rules effective January 2025, has forced every pre-IPO team to re-examine how they construct their peer valuation benchmarks. The days of pulling a handful of listed comparables from a Bloomberg screen and averaging their trailing P/E ratios are over. Regulators now expect a documented, source-verifiable methodology that ties each multiple back to specific figures in the prospectus or annual report of the comparator company. For a Hong Kong Main Board applicant, the peer valuation table is no longer a marketing slide; it is a piece of evidential disclosure that the Listing Division will test against the issuer’s own financial trajectory. Building this table correctly from raw prospectus data—not from a data terminal’s pre-packaged multiples—is the difference between a smooth listing process and a round of painful follow-up questions that can delay the timetable by weeks.

The Data Sourcing Hierarchy: Why Prospectus Data Trumps Terminal Aggregates

The primary source for any peer valuation multiple must be the comparator’s own published filings. Bloomberg and Refinitiv calculate trailing multiples using a proprietary algorithm that may mix audited annual figures with unaudited interim numbers, and their enterprise value calculations often include cash and debt items from the most recent balance sheet without adjusting for non-recurring items. An analyst building a benchmarking table for a HKEX Main Board listing should start with the comparator’s latest prospectus (if the peer itself listed within the last three years) or its most recent annual report filed with the HKEX or the SEC. The SFC’s Code of Conduct for Sponsors (paragraph 17.4) requires that all material assumptions in a valuation be traceable to a verifiable source. A Bloomberg screen is not a verifiable source for regulatory purposes.

Prospectus-to-Prospectus Matching for Recent IPOs

When the issuer and its peers have all listed within the same 24-36 month window, the cleanest approach is to extract revenue, net profit, and adjusted EBITDA figures from the historical financial information section of each peer’s prospectus. These figures are audited to the standard required by HKEX Listing Rule 4.10 and are presented in a consistent format: three years of income statements, balance sheets, and cash flow statements, with notes that disclose non-recurring items. For example, if the issuer is a biotech company listing under Chapter 18A, its peers are likely also Chapter 18A companies, and their prospectuses will contain the same core R&D expenditure breakdown and cash burn rate disclosures. Extracting P/E or EV/Revenue multiples from these documents requires the analyst to compute the market capitalisation as at the peer’s own listing date, then apply the peer’s IPO price to its post-IPO share count. This produces a multiple that is directly comparable to the issuer’s own pro-forma multiples at its intended offer price.

Annual Report Data for Established Comparators

For peers that listed more than five years ago, the annual report is the appropriate source. The HKEX’s Appendix 16 to the Listing Rules mandates that annual reports contain a five-year financial summary, which provides the consistent time series needed for trailing multiples. The analyst must note the exact page reference for each data point. A common error is to use the headline “profit attributable to equity holders” without checking whether the annual report contains a non-recurring adjustment note. The HKEX’s Guidance Letter GL56-13 (January 2024 update) explicitly states that sponsors must disclose any adjustments made to reported earnings when calculating valuation multiples. If the peer had a one-off impairment in the most recent year, the analyst must either use the adjusted figure from the management discussion and analysis section or explicitly flag the impairment in a footnote to the benchmarking table.

Constructing the Multiple Matrix: EV/EBITDA, P/E, and Sector-Specific Metrics

The core of the benchmarking table is a matrix of three to five valuation multiples, each calculated from the same set of underlying financial data. The standard set for a Hong Kong Main Board listing includes trailing P/E, forward P/E (based on consensus estimates if available, otherwise the issuer’s own forecast), EV/EBITDA, and EV/Revenue. For sectors such as property development, price-to-book (P/B) is standard; for technology companies with negative earnings, EV/Sales or EV/ Gross Profit may be the primary metric. Each multiple must be calculated using the same date for market capitalisation—typically the last trading day before the prospectus is issued, or the date of the latest available closing price. The HKEX Listing Division will check that the market cap date is consistent across all comparators.

The Enterprise Value Calculation Protocol

Enterprise value is the sum of market capitalisation, total debt, minority interests, and preferred equity, minus cash and cash equivalents. The debt and cash figures must come from the same balance sheet date as the earnings figure used in the multiple. For example, if the trailing P/E uses earnings for the year ended 31 December 2024, the EV calculation must use the debt and cash balances as at 31 December 2024. This is not always straightforward: a peer may have issued a convertible bond after the balance sheet date but before the valuation date. The analyst must decide whether to include the conversion option as debt or equity, and must document that decision with reference to HKAS 32 (Financial Instruments: Presentation). The SFC’s March 2023 circular on valuation disclosures in listing documents reminds sponsors that any departure from standard accounting treatment in the EV calculation must be justified in the valuation methodology section of the prospectus.

Normalising for Non-Recurring Items and Capital Structure Differences

No two comparators have identical capital structures or earnings quality. The benchmarking table must show both the unadjusted multiple and a normalised multiple that strips out the effect of non-recurring items. For a peer that recorded a gain on disposal of a subsidiary in the most recent year, the normalised EBITDA should exclude that gain. The adjustment should be cross-referenced to the note number in the peer’s annual report. Similarly, if a peer has a significantly different tax rate due to a jurisdictional mix (e.g., a Cayman-incorporated company with a Hong Kong operating subsidiary versus a BVI-incorporated company with a PRC operating entity), the effective tax rate should be disclosed alongside the P/E multiple. The HKEX Listing Rules require that the “basis of valuation” section in the prospectus explain how differences in gearing, tax, and growth rates between the issuer and its peers have been considered. A simple table with no footnotes will not satisfy this requirement.

Cross-Jurisdictional Comparators: Handling US-Listed and A-Share Peers

A Hong Kong issuer’s peer group may include companies listed on the NYSE, Nasdaq, or the Shanghai/Shenzhen stock exchanges. Each jurisdiction uses different accounting standards (HKFRS, US GAAP, PRC GAAP) and different disclosure conventions for non-recurring items. The benchmarking table must reconcile these differences or, at minimum, flag them. The HKEX’s Joint Policy Statement on the Regulation of Sponsors (May 2023) emphasises that sponsors must not simply assume comparability across accounting frameworks without adjustment.

Converting US GAAP to HKFRS for Multiple Calculation

US-listed peers report under US GAAP, which treats certain items—such as share-based compensation and impairment of goodwill—differently from HKFRS. For a technology peer, share-based compensation can represent 15-25% of reported revenue. If the analyst uses US GAAP net income without adding back share-based compensation, the P/E multiple will be artificially inflated. The correct approach is to reconstruct the peer’s income statement on an HKFRS-equivalent basis, using the reconciliation notes that many US-listed companies provide in their 20-F filings. The SEC’s Regulation S-X requires a reconciliation to IFRS for foreign private issuers that use US GAAP, but Hong Kong-incorporated peers listed in the US may not provide this. In that case, the analyst must estimate the adjustment using disclosed share-based compensation expense and document the methodology in a footnote.

A-Share Peers and the PRC GAAP Adjustments

A-Share companies report under PRC GAAP, which has specific treatments for government grants, impairment of long-lived assets, and business combinations under common control. The most significant difference for valuation purposes is the treatment of deferred tax assets: PRC GAAP is more conservative in recognising deferred tax assets on tax losses, which can understate net income in loss-making companies. For a biotech issuer comparing itself to A-share listed biotech peers, the analyst should adjust the peer’s net income to reflect the deferred tax asset that would be recognised under HKFRS. The adjustment amount can be found in the peer’s A-share annual report under the deferred tax note. The HKEX Listing Division has, in recent years, asked sponsors to provide a reconciliation table showing the impact of accounting standard differences on the peer multiples, particularly for issuers in the healthcare and technology sectors.

The Presentation Layer: Footnotes, Ranges, and the Discount/Premium Analysis

The final benchmarking table must be presented in a format that allows the Listing Division and potential investors to understand the range of multiples and the issuer’s positioning within that range. A common structure is a table with 10-15 comparators, each row showing the company name, stock code, market capitalisation, enterprise value, revenue, EBITDA, net profit, and the calculated multiples. The final row shows the median and mean for each multiple. Below the table, a separate section shows the issuer’s own multiples at the mid-point of its offer price range, alongside the peer median. The difference—expressed as a percentage discount or premium—is the key output.

Footnote Disclosure Requirements

Every adjustment made to a peer’s reported figures must be disclosed in a footnote. The HKEX’s Guidance Letter GL41-12 (updated December 2024) specifies that footnotes should include the source document and page number, the nature of the adjustment, and the amount. For example: “(1) Peer A’s EBITDA for FY2024 excludes a HKD 123.4 million impairment of goodwill as disclosed in Note 15 of its 2024 Annual Report (page 78). The unadjusted EBITDA was HKD 456.7 million; adjusted EBITDA is HKD 580.1 million.” A table with fewer than five footnotes is unlikely to withstand regulatory scrutiny.

The Discount/Premium Range and Its Justification

The issuer must explain why it deserves a premium or discount relative to the peer median. The explanation should reference objective factors: growth rate differential, margin differential, market position, or regulatory environment. A statement such as “the issuer commands a 15% premium due to its superior growth profile” is insufficient unless the growth rates are quantified in the same table. The proper approach is to include a separate column showing each peer’s three-year revenue CAGR and EBITDA margin, so the reader can see the correlation. The HKEX Listing Division has, in at least three known cases in 2024, requested additional justification where the issuer’s implied valuation was more than 30% above or below the peer median without a clear, data-supported explanation.

Actionable Takeaways

1. Build the peer valuation table from the comparator’s own prospectus or annual report, not from a terminal’s pre-calculated multiples, to satisfy the SFC’s source-verification requirement under paragraph 17.4 of the Code of Conduct for Sponsors.

2. Normalise every peer’s earnings for non-recurring items and accounting standard differences, and document each adjustment with a footnote citing the exact note number and page from the source filing.

3. Calculate enterprise value using debt and cash figures from the same balance sheet date as the earnings period used for the multiple, and disclose any convertible instruments or minority interests separately.

4. Present the issuer’s implied multiples at the mid-point of its offer price range alongside the peer median, and quantify the discount or premium as a percentage with a supporting table of growth rates and margins.

5. Ensure the final table includes a minimum of five footnotes covering adjustments, source references, and methodology choices, as the HKEX Listing Division will test the table against the disclosure standards in GL41-12 and GL56-13.